
USD
( +0.00%
At Close (As of Jan 1, 1970)
$227.19M
Market Cap
-
P/E Ratio
-2.34
EPS
$3.67
52 Week High
$0.98
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$4.8M |
| Total Revenue | $0 |
| Cost Of Revenue | $4.8M |
| Costof Goods And Services Sold | $4.8M |
| Operating Income | -$125M |
| Selling General And Administrative | $28M |
| Research And Development | $97M |
| Operating Expenses | $120M |
| Investment Income Net | - |
| Net Interest Income | $9.3M |
| Interest Income | $10M |
| Interest Expense | $748K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $4.8M |
| Income Before Tax | -$116M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$116M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$115M |
| Ebitda | -$110M |
| Net Income | -$116M |
| Field | Value (USD) |
|---|---|
| Total Assets | $185M |
| Total Current Assets | $167M |
| Cash And Cash Equivalents At Carrying Value | $164M |
| Cash And Short Term Investments | $164M |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $22M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $0 |
| Other Current Assets | $2.7M |
| Other Non Current Assets | - |
| Total Liabilities | $33M |
| Total Current Liabilities | $27M |
| Current Accounts Payable | $4.9M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $10M |
| Total Non Current Liabilities | $5.6M |
| Capital Lease Obligations | $16M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $16M |
| Other Current Liabilities | $12M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $152M |
| Treasury Stock | - |
| Retained Earnings | -$349M |
| Common Stock | $1K |
| Common Stock Shares Outstanding | $49M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$4.8M |
| Total Revenue | $0 |
| Cost Of Revenue | $4.8M |
| Costof Goods And Services Sold | $4.8M |
| Operating Income | -$125M |
| Selling General And Administrative | $28M |
| Research And Development | $97M |
| Operating Expenses | $120M |
| Investment Income Net | - |
| Net Interest Income | $9.3M |
| Interest Income | $10M |
| Interest Expense | $748K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $4.8M |
| Income Before Tax | -$116M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$116M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$115M |
| Ebitda | -$110M |
| Net Income | -$116M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Cabaletta Bio, Inc. is a clinical-stage biotechnology company based in Philadelphia, Pennsylvania, specializing in the development of advanced T-cell therapies aimed at targeting B-cell-mediated autoimmune diseases. With a robust pipeline driven by proprietary research and a commitment to improving patient outcomes, the company is positioned to transform treatment paradigms in this sector. Leveraging its expertise in immunotherapy and focusing on patient-centric initiatives, Cabaletta Bio presents an attractive investment opportunity for institutional investors looking to capitalize on innovative solutions in the biopharmaceutical industry.